Whitehawk Therapeutics data at SGO 2026 positions MUC16 as superior ADC target
Whitehawk Therapeutics (NASDAQ:WHWK), a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), presented compelling real-world evidence at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.






-640x360.webp&w=3840&q=75)



